Danes launch $3.4 million bid to prove resveratrol benefits

Danes launch $3.4 million bid to prove resveratrol benefits

Researchers will evaluate the effect of the resveratrol on the management of conditions such as metabolic syndrome, osteoporosis and inflammation.

Researchers in Denmark will begin a five-year, $3.4 million study this summer to investigate the long-term effects of resveratrol in humans.

Backed by the Danish Council for Strategic Research, a government-funded agency, the project will take place at Aarhus University under the leadership of Steen Bønløkke Pedersen and using resveratrol supplied by Denmark-based ingredients manufacturer Fluxome.

Beginning in June 2011 volunteers will be asked to consume Fluxome resveratrol for a period of 12 months. Researchers will then evaluate the effect of the resveratrol on the management of conditions such as metabolic syndrome, osteoporosis and inflammation.

Resveratrol is found naturally in red wine but can also be manufactured. Fluxome produces the ingredient naturally by fermenting a strain of yeast called Saccharomyces cerevisiae.

Meanwhile, researchers in the U.S. say taking resveratrol with the drug rapamycin could boost the body’s ability to fight off breast cancer cells. The results were published in the journal Cancer Letters.

Charis Eng, who led the study at the Cleveland Clinic in Ohio, said: “Our findings show that resveratrol seems to mitigate rapamycin-induced drug resistance in breast cancers, at least in the laboratory.”

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish